Ascentage Pharma Group International
HKEX:6855
Intrinsic Value
Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. [ Read More ]
The intrinsic value of one
Ascentage Pharma Group International
stock under the Base Case scenario is
23.56
HKD.
Compared to the current market price of 16.8 HKD,
Ascentage Pharma Group International
is
Undervalued by 29%.
Ascentage Pharma Group International's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
Ascentage Pharma Group International or that its price is influenced by factors unrelated to fundamentals.
Ascentage Pharma Group International's market capitalization is 4.9B HKD.
Ascentage Pharma Group International stock price is 16.8 HKD.
Ascentage Pharma Group International stock price (16.8 HKD) is 29% less than its Intrinsic Value (23.56 HKD).
Ascentage Pharma Group International. Open DCF Valuation
Ascentage Pharma Group International stock price (16.8 HKD) is 29% less than its Relative Value (23.56 HKD). Open Relative Valuation
Ascentage Pharma Group International has upside potential of 94% compared to the average analyst price target.
Open Wall St Estimates
Ascentage Pharma Group International's long-term assets (3B CNY) exceed its long-term liabilties (2B CNY).
Ascentage Pharma Group International's Revenue has grown by 6% over the past 12 months.
Ascentage Pharma Group International has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (1B CNY).
Ascentage Pharma Group International's short-term assets (1B CNY) exceed its short-term liabilties (934m CNY).
Ascentage Pharma Group International's ROE (Return on Equity) has significantly decreased in the last 3 years from -78% to -395%, and is approaching profitability.
Ascentage Pharma Group International's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -139% to -67%, and is approaching profitability.
Ascentage Pharma Group International has negative Operating Income for the last twelve months.
Ascentage Pharma Group International has negative Net Income for the last twelve months.
Ascentage Pharma Group International's ROE (Return on Equity) for the past 12 months is negative and is equal to -395%.
Ascentage Pharma Group International's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -67%.
Ascentage Pharma Group International's Revenue is forecast to grow at a rate of 60% per year over the next 3 years.
Ascentage Pharma Group International has positive Gross Profit for the last twelve months.
Ascentage Pharma Group International has negative Free Cash Flow for the last twelve months.
Ascentage Pharma Group International's Revenue has been growing by an exceptional 161% per year for the last 3 years.
Ascentage Pharma Group International has negative three-year average ROE (Return on Equity): -131%. The company is not efficient at transforming stockholders' equity into net income.
Ascentage Pharma Group International has negative three-year average ROIC (Return on Invested Capital): -91%. The company is not efficient at using invested capital to generate operating income.
Ascentage Pharma Group International's D/E (Debt to Equity) is very high and is equal to 21.5.
Ascentage Pharma Group International's Altman Z-Score is very low and is equal to -2.6.
Ascentage Pharma Group International doesn't generate enough operating income (-874m CNY) to safely cover interest payments on its debt (28m CNY).
Valuation Backtest
Ascentage Pharma Group International
Run backtest to discover the historical profit from buying and selling
Ascentage Pharma Group International
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ascentage Pharma Group International
Balance Sheet Decomposition
Ascentage Pharma Group International
| Current Assets | 1.3B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 145.9m |
| Other Current Assets | 104.5m |
| Non-Current Assets | 1.2B |
| Long-Term Investments | 18.9m |
| PP&E | 957.1m |
| Intangibles | 110.1m |
| Other Non-Current Assets | 70.1m |
| Current Liabilities | 934.2m |
| Accounts Payable | 72.4m |
| Short-Term Debt | 120m |
| Other Current Liabilities | 741.7m |
| Non-Current Liabilities | 1.5B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 326.6m |
Earnings Waterfall
Ascentage Pharma Group International
|
Revenue
|
222m
CNY
|
|
Cost of Revenue
|
-30.5m
CNY
|
|
Gross Profit
|
191.4m
CNY
|
|
Operating Expenses
|
-1.1B
CNY
|
|
Operating Income
|
-874m
CNY
|
|
Other Expenses
|
-51.6m
CNY
|
|
Net Income
|
-925.6m
CNY
|
Free Cash Flow Analysis
Ascentage Pharma Group International
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Ascentage Pharma Group International's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
Ascentage Pharma Group International's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ascentage Pharma Group International's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Score
Ascentage Pharma Group International's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ascentage Pharma Group International
According to Wall Street analysts, the average 1-year price target for
Ascentage Pharma Group International
is 32.53 HKD
with a low forecast of 29.59 HKD and a high forecast of 37.8 HKD.
Shareholder Return
Price
Ascentage Pharma Group International
| Average Annual Return | -5.29% |
| Standard Deviation of Annual Returns | 28.02% |
| Max Drawdown | -79% |
| Market Capitalization | 4.9B HKD |
| Shares Outstanding | 288 974 116 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Ascentage Pharma Group International
Country
Industry
Market Cap
Dividend Yield
Description
Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 613 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
Ascentage Pharma Group International
stock under the Base Case scenario is
23.56
HKD.
Compared to the current market price of 16.8 HKD,
Ascentage Pharma Group International
is
Undervalued by 29%.
You don't have any saved screeners yet
